Fig. 3.
Progression-free survival for Asian subgroup. CI confidence interval, HR hazard ratio, N number of patients randomized in Asian subgroup, Q4W every 4 weeks. HR < 1 favors denosumab
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.